研究单位：[1]Ipsen[2]West China Hospital of Sichuan University Sichuan,Chengdu,China,610041[3]The First Affiliated Hospital,Sun Yat-Sen University Guangzhou,Guangdong,China,510080[4]Harbin Medical University Cancer Hospital Harbin,Helongjiang,China,150081[5]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China,430030[6]Qilu Hospital Of Shandong University Jinan,Shandong,China,250012[7]The First Affiliated Hospital Of Xi'an Jiaotong University Shanxi,Xi-an,China,710061[8]The First affiliated hospital of Xiamen University Fujian,Xiamen,China,361003[9]The second affiliated hospital of Zhejiang University School of Medicine Hangzhou,Zhejiang,China,310009[10]The First Affiliated Hospital of College of Medicine,Zhejiang University Hangzhou,Zhejiang,China,310058[11]The First Affiliated Hospital of Zhengzhou University Henan,Zhengzhou,China,450052[12]Cancer Hospital Chinese Academy of Sciences Beijing,China,100021[13]Beijing Cancer Hospital Beijing,China,100142[14]Peking University Third Hospital Beijing,China,100191[15]Zhongshan Hospital Affiliated to Fudan University Shanghai,China,200032[16]Fudan University Shanghai Cancer Centre Shanghai,China,200433
研究目的：
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.
The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion of the main study period, approximately five participants will continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for 24 weeks.
